Partnering with Pharmaceutical Companies

Lx®-based ADCs offer advantages over competing mAb conjugation technologies in performance and production:

  • Lx®-ADCs are stable and robust, with an efficacy and therapeutic window outperforming benchmark ADCs
  • Even in tumors with low functional copy number targets (as e.g. HER2+ low expression tumors) Lx®-ADCs have a good efficacy
  • Lx®-ADCs are produced in a one-step reaction, by combining a stable Lx®-payload semifinal product with a mAb in a buffered aqueous solution under mild reaction conditions

For other advantages, see the technology section.
If you are interested and want to discuss possibilities for cooperation with LinXis, please contact HendrikJan Houthoff.